Dr. Prieto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Dermatopathology, 1995 - 1996
- New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1991 - 1994
- Universidad Central de BarcelonaPhD, Cellular Biology, PhD cum laude, 1989 - 1991
- OtherClass of 1986, MD
Certifications & Licensure
- TX State Medical License 2001 - 2026
- NC State Medical License 1996 - 2006
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Dermatopathology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsAppropriate use criteria in dermatopathology: Initial recommendations from the American Society of DermatopathologyClaudia I. Vidal, Eric A. Armbrect, Aleodor A. Andea, Angela K. Bohlke, Nneka I. Comfere
Journal of Cutaneous Pathology. 2018-08-01 - 7 citationsMeasurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?Pelin Yildiz, Phyu P. Aung, Denái R. Milton, Chad Hruska, Doina Ivan
The American Journal of Dermatopathology. 2020-05-01 - 559 citationsNeoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N. Amaria, Sangeetha M. Reddy, Hussein Abdul-Hassan Tawbi, Michael A. Davies, Merrick I. Ross
Nature Medicine. 2018-10-08
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Melanoma Coexisting with Solar Elastosis: A Potential Pitfall in the Differential Diagnosis Between Nevus and MelanomaMichael T Tetzlaff, Victor G Prieto, Phyu P Aung, Priyadharsini Nagarajan, ScienceDirect
- Join now to see all
Press Mentions
- Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%October 25th, 2023
- Pembrolizumab Trial in Advanced Melanoma Shows Major Pathological Response Exceeding 50%October 25th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: